Apogee Therapeutics Reports $159.9 Million Net Loss, Enters Merger Agreement with AbbVie

Apogee Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $159.9 million for the six months ended June 30, 2026, compared to a loss of $121.4 million for the same period in 2025. Total operating expenses increased to $178.8 million from $136.3 million year-over-year, driven primarily by higher research and development costs, which rose to $128.1 million from $102.1 million. General and administrative expenses also saw an increase, totaling $46.3 million, up from $34.2 million in the prior year.

The company’s cash and cash equivalents stood at $105.6 million as of June 30, 2026, alongside $866.4 million in marketable securities and $321.9 million in long-term marketable securities. This positions Apogee to fund its operations for at least the next 12 months, according to management's estimates. The increase in cash reserves was bolstered by financing activities, which generated $518.2 million, primarily from the issuance of common stock and a revenue share agreement with Blackstone Life Sciences.

Strategically, Apogee entered into a Merger Agreement with AbbVie Inc. on June 18, 2026, which is expected to close in the third quarter of 2026, subject to various conditions including stockholder approval. The merger will see Apogee become a wholly-owned subsidiary of AbbVie, with shareholders receiving $135.11 per share in cash. The company also initiated a revenue share agreement with BXLS, which provided an upfront payment of $100 million, with additional funding contingent on the success of clinical trials for its lead product, zumilokibart.

Operationally, Apogee is advancing its clinical pipeline, particularly with zumilokibart, which is in Phase 2 trials for atopic dermatitis and asthma. The company reported positive interim results from these trials, indicating a favorable safety profile and significant efficacy in reducing symptoms. The ongoing development of other product candidates, including APG279 and APG273, is also a focus, with plans for further clinical trials expected to be announced in the coming months.

Looking ahead, Apogee anticipates continued increases in research and development expenses as it progresses through clinical trials and prepares for potential commercialization. The company remains focused on addressing unmet medical needs in inflammatory and immunology markets, while navigating the complexities of its merger and financing arrangements.